Infectious bronchitis virus S2 expressed from recombinant virus confers broad protection against challenge
- PMID: 24758118
- DOI: 10.1637/10641-081613-Reg.1
Infectious bronchitis virus S2 expressed from recombinant virus confers broad protection against challenge
Abstract
We developed a recombinant Newcastle disease virus (NDV) LaSota (rLS) expressing the infectious bronchitis virus (IBV) S2 gene (rLS/IBV.S2). The recombinant virus showed somewhat-reduced pathogenicity compared to the parental lentogenic LaSota strain but effectively elicited hemagglutination inhibition antibodies against NDV and protected chickens against lethal challenge with virulent NDV/CA02. IBV heterotypic protection was assessed using a prime-boost approach with a commercially available attenuated IBV Massachusetts (Mass)-type vaccine. Specific-pathogen-free chickens primed ocularly with rLS/IBV.S2 at 4 days of age and boosted with Mass at 18 days of age were completely protected against challenge at 41 days of age with a virulent Ark-type strain. In a second experiment, we compared protection conferred by priming with rLS/IBV.S2 and boosting with Mass (rLS/IBV.S2+Mass) versus priming and boosting with Mass (Mass+Mass). We also modified the timing of vaccination to prime at 1 day of age and boost at 12 days of age. Challenge with virulent Ark was performed at 21 days of age. Based on clinical signs, both vaccinated groups appeared equally protected against challenge compared to unvaccinated challenged chickens. Viral loads in lachrymal fluids of birds receiving rLS/IBV.S2+Mass showed a clear tendency of improved protection compared to Mass+Mass; however, the difference did not achieve statistical significance. A significant difference (P < 0.05) was determined between these groups regarding incidence of detection of challenge IBV RNA in the trachea; viral RNA was detected in 50% of rLS/IBV.S2+Mass-vaccinated chickens while chickens vaccinated with Mass+Mass and unvaccinated challenged controls showed 84 and 90% incidence of IBV RNA detection in the trachea, respectively. These results demonstrate that overexposing the IBV S2 to the chicken immune system by means of a vectored vaccine, followed by boost with whole virus, protects chickens against IBV showing dissimilar S1.
Similar articles
-
Limited Protection Conferred by Recombinant Newcastle Disease Virus Expressing Infectious Bronchitis Spike Protein.Avian Dis. 2020 Mar;64(1):53-59. doi: 10.1637/0005-2086-64.1.53. Avian Dis. 2020. PMID: 32267125
-
Infectious Bronchitis Virus S2 of 4/91 Expressed from Recombinant Virus Does Not Protect Against Ark-Type Challenge.Avian Dis. 2017 Sep;61(3):397-401. doi: 10.1637/11632-032017-ResNoteR. Avian Dis. 2017. PMID: 28957002
-
Enhanced Protection by Recombinant Newcastle Disease Virus Expressing Infectious Bronchitis Virus Spike Ectodomain and Chicken Granulocyte-Macrophage Colony-Stimulating Factor.Avian Dis. 2021 Sep;65(3):364-372. doi: 10.1637/aviandiseases-D-21-00032. Avian Dis. 2021. PMID: 34427409
-
Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.Avian Pathol. 2003 Dec;32(6):567-82. doi: 10.1080/03079450310001621198. Avian Pathol. 2003. PMID: 14676007 Free PMC article. Review.
-
Avian infectious bronchitis virus.Rev Sci Tech. 2000 Aug;19(2):493-508. doi: 10.20506/rst.19.2.1228. Rev Sci Tech. 2000. PMID: 10935276 Review.
Cited by
-
A Temperature-Sensitive Recombinant of Avian Coronavirus Infectious Bronchitis Virus Provides Complete Protection against Homologous Challenge.J Virol. 2022 Sep 14;96(17):e0110022. doi: 10.1128/jvi.01100-22. Epub 2022 Aug 16. J Virol. 2022. PMID: 35972294 Free PMC article.
-
Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use.Viruses. 2022 May 6;14(5):975. doi: 10.3390/v14050975. Viruses. 2022. PMID: 35632717 Free PMC article. Review.
-
Identification of Amino Acids within Nonstructural Proteins 10 and 14 of the Avian Coronavirus Infectious Bronchitis Virus That Result in Attenuation In Vivo and In Ovo.J Virol. 2022 Mar 23;96(6):e0205921. doi: 10.1128/jvi.02059-21. Epub 2022 Jan 19. J Virol. 2022. PMID: 35044208 Free PMC article.
-
Reverse Genetics and Its Usage in the Development of Vaccine Against Poultry Diseases.Methods Mol Biol. 2022;2411:77-92. doi: 10.1007/978-1-0716-1888-2_4. Methods Mol Biol. 2022. PMID: 34816399
-
Identification of Novel T-Cell Epitopes on Infectious Bronchitis Virus N Protein and Development of a Multi-epitope Vaccine.J Virol. 2021 Aug 10;95(17):e0066721. doi: 10.1128/JVI.00667-21. Epub 2021 Aug 10. J Virol. 2021. PMID: 34105997 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
